An experimental daily pill combined with standard chemotherapy shrank tumors or stopped their growth in the vast majority of patients with advanced pancreatic cancer, according to early clinical trial results presented Friday at the EORTC-NCI-AACR Symposium in Barcelona.
The phase ½ trial tested daraxonrasib, an oral medication developed by California-based Revolution Medicines, alongside two standard intravenous chemotherapy drugs, gemcitabine and nab-paclitaxel. It enrolled 61 patients whose pancreatic cancer had already spread to other organs and who had not yet received treatment for their advanced disease.
Pancreatic cancer is among the hardest cancers to treat, in part because more than half of patients are diagnosed only after the disease has spread. In major clinical trials for metastatic disease, chemotherapy alone typically shrinks tumors in 23% to 42% of patients, with the cancer usually resuming growth within five to six months and most patients surviving between 8 and 11 months. National Cancer Institute data shows only about 3% of patients with distant-stage disease live five years past diagnosis.
In this new study, which followed patients for a median of 18 months, tumors shrank in 60.7% of cases, including 8.2% where they disappeared entirely on scans. The combination halted tumor growth altogether in 90.2% of participants.
Patients went a median of 12.8 months before their cancer worsened — nearly double what is typically seen with chemotherapy alone — and 76.6% were still alive after one year.
“We are now seeing not only substantial tumor shrinkages, including complete responses, but also durable disease control, with median progression-free survival exceeding one year,” said Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who led the study.
How the drug works
More than 90% of pancreatic cancers are driven by a faulty gene called RAS, which keeps tumors growing. Daraxonrasib is designed to shut off that growth signal — a target scientists long considered beyond the reach of medication.
Dr. Elena Garralda, chair of the symposium and co-director of the clinical research program at the Vall d’Hebron Institute of Oncology in Spain, who was not involved in the research, said the results show RAS-targeted drugs can be combined with existing treatments from the start of care to potentially produce longer-lasting benefits.
Side effects included rash, diarrhea, fatigue and low blood cell counts tied to chemotherapy, most of which were manageable with standard care. Only 5% of patients stopped treatment because of side effects linked to daraxonrasib.
Limitations and next steps
Researchers caution the findings come with important caveats. Because this was an early-phase, single-group study of 61 people, every participant received the experimental combination — there was no comparison group taking standard chemotherapy alone. That means doctors cannot yet say definitively how much better the new regimen performs or whether it extends overall survival.
The results also apply strictly to metastatic pancreatic cancer. RAS mutations drive several other cancers, including certain lung, colorectal and gynecological cancers, but separate studies would be needed to test the combination in those diseases.
The trial was funded by Revolution Medicines. To confirm whether these early signals translate into a lasting survival benefit, researchers have launched a larger, randomized Phase 3 trial called RASolute-303, which will directly compare daraxonrasib — alone and combined with chemotherapy — against standard chemotherapy alone.
